Daily Newsroom
Follow market-moving stories, policy signals, and company developments curated by the editorial desk.
Lead story
Goldman Sachs analysts report that Iran's willingness to permit safe passage, rather than tanker availability, is the primary obstacle to restoring oil flows through the Strait of Hormuz amid escalating U.S.-Iran tensions.
Shares of Indian drugmaker Dr. Reddy's Laboratories fell sharply after it announced a delay in the commercial supply of its semaglutide product, citing quality issues with the active pharmaceutical ingredient.
The German pharmaceutical packaging firm lifted its full-year revenue and earnings targets, citing a resolution to a dispute that had previously triggered a profit warning in December 2025.
Australia's benchmark S&P/ASX 200 index closed down 0.26% on Thursday, dragged lower by losses in the materials and metals sectors. Major miners like Rio Tinto and South32 led the declines, while market volatility ticked higher.
The Japanese parent company of Uniqlo reported a significant third-quarter earnings beat, citing resilience amid supply chain disruptions, and raised its full-year operating profit guidance.
The shipping and logistics firm reported second-quarter revenue and earnings that surpassed analyst expectations, though EBITDA fell short as geopolitical disruptions impacted operations.
UK outsourcing firm Capita plc warned that issues with a major pension contract will significantly impact its 2026 profit and cash flow, overshadowing modest revenue growth and strong contract wins in the first half of the year.
Shares of Dr. Reddy’s Laboratories fell sharply on Thursday after the company announced a delay in the commercial supply of its popular weight-loss and diabetes drug, semaglutide, due to an issue with its active ingredient.
Analysts at Berenberg have started coverage on UK leisure group Saga with a 'Buy' recommendation, forecasting approximately 62% upside driven by a successful business overhaul, robust cruise demand, and a clear path to reduced debt.
